Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chemotherapy Induced Neutropenia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Chemotherapy Induced Neutropenia - Pipeline Review, H1 2015', provides an overview of the Chemotherapy Induced Neutropenia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chemotherapy Induced Neutropenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Chemotherapy Induced Neutropenia Overview 10 Therapeutics Development 11 Pipeline Products for Chemotherapy Induced Neutropenia - Overview 11 Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis 12 Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies 13 Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes 16 Chemotherapy Induced Neutropenia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Chemotherapy Induced Neutropenia - Products under Development by Companies 21 Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes 24 Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 25 Bio-Ker s.r.l 25 Biogenomics Limited 26 Bolder Biotechnology, Inc. 27 Cellerant Therapeutics, Inc. 28 Coherus BioSciences, Inc. 29 Dong-A Socio Group 30 Generon (Shanghai) Corporation Ltd. 31 Hanmi Pharmaceuticals, Co. Ltd. 32 Io Therapeutics, Inc. 33 Mycenax Biotech Inc. 34 Myelo Therapeutics GmbH 35 Octapharma AG 36 PharmaEssentia Corporation 37 Reliance Life Sciences Pvt. Ltd. 38 Richter Gedeon Nyrt. 39 Sandoz Inc. 40 Sandoz International GmbH 41 Teva Pharmaceutical Industries Limited 42 UAB Profarma 43 USV Limited 44 Welichem Biotech Inc. 45 XBiotech USA, Inc. 46 Chemotherapy Induced Neutropenia - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 balugrastim - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 BBT-007 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BBT-015 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 BBT-018 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 BK-0026 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 F-627 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 filgrastim - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 filgrastim - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 filgrastim - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 filgrastim - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 filgrastim - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 filgrastim - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 filgrastim - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 filgrastim (recombinant) - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 GW-003 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 HM-10460A - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 IRX-4310 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 lipegfilgrastim - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Myelo-001 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 pegfilgrastim - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 pegfilgrastim - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 pegfilgrastim - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 pegfilgrastim - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 pegfilgrastim - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 pegfilgrastim - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 pegfilgrastim - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 pegfilgrastim - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Recombinant Protein for Chemotherapy Induced Neutropenia - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 romyelocel-L - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 TXA-302 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 WBI-2100 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Chemotherapy Induced Neutropenia - Recent Pipeline Updates 92 Chemotherapy Induced Neutropenia - Dormant Projects 98 Chemotherapy Induced Neutropenia - Discontinued Products 100 Chemotherapy Induced Neutropenia - Product Development Milestones 101 Featured News & Press Releases 101 Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 101 Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 102 May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 103 Mar 25, 2014: Sandoz receives approval for biosimilar filgrastim in Japan 103 Nov 18, 2013: Teva announces Launch of LONQUEX Injection 104 Jul 22, 2013: Zarzio overtakes Neupogen and Granocyte to become most prescribed daily G-CSF in Europe 105 Jun 03, 2013: Teva's Lonquex Receives Positive Opinion From CHMP For Reduction Of Chemotherapy-induced Neutropenia 105 Apr 25, 2013: Sandoz Files For Marketing Authorization Of Biosimilar Filgrastim In Japan 106 Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 106 Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 107 Appendix 108 Methodology 108 Coverage 108 Secondary Research 108 Primary Research 108 Expert Panel Validation 108 Contact Us 109 Disclaimer 109
List of Tables Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2015 11 Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2015 16 Comparative Analysis by Late Stage Development, H1 2015 17 Comparative Analysis by Clinical Stage Development, H1 2015 18 Comparative Analysis by Early Stage Development, H1 2015 19 Comparative Analysis by Unknown Stage Development, H1 2015 20 Products under Development by Companies, H1 2015 21 Products under Development by Companies, H1 2015 (Contd..1) 22 Products under Development by Companies, H1 2015 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2015 24 Chemotherapy Induced Neutropenia - Pipeline by Bio-Ker s.r.l, H1 2015 25 Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H1 2015 26 Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H1 2015 27 Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H1 2015 28 Chemotherapy Induced Neutropenia - Pipeline by Coherus BioSciences, Inc., H1 2015 29 Chemotherapy Induced Neutropenia - Pipeline by Dong-A Socio Group, H1 2015 30 Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2015 31 Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 32 Chemotherapy Induced Neutropenia - Pipeline by Io Therapeutics, Inc., H1 2015 33 Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc., H1 2015 34 Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H1 2015 35 Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H1 2015 36 Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corporation, H1 2015 37 Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 38 Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2015 39 Chemotherapy Induced Neutropenia - Pipeline by Sandoz Inc., H1 2015 40 Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2015 41 Chemotherapy Induced Neutropenia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 42 Chemotherapy Induced Neutropenia - Pipeline by UAB Profarma, H1 2015 43 Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H1 2015 44 Chemotherapy Induced Neutropenia - Pipeline by Welichem Biotech Inc., H1 2015 45 Chemotherapy Induced Neutropenia - Pipeline by XBiotech USA, Inc., H1 2015 46 Assessment by Monotherapy Products, H1 2015 47 Number of Products by Stage and Target, H1 2015 49 Number of Products by Stage and Mechanism of Action, H1 2015 51 Number of Products by Stage and Route of Administration, H1 2015 53 Number of Products by Stage and Molecule Type, H1 2015 55 Chemotherapy Induced Neutropenia Therapeutics - Recent Pipeline Updates, H1 2015 92 Chemotherapy Induced Neutropenia - Dormant Projects, H1 2015 98 Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H1 2015 99 Chemotherapy Induced Neutropenia - Discontinued Products, H1 2015 100
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.